Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Watches of Switzerland backs FY guidance after 'good' holiday trading

(Sharecast News) - Watches of Switzerland backed its full-year guidance on Thursday as it said trading in the 13 weeks to 26 January was in line with its expectations. The luxury watch retailer said trading over the holiday period in the UK and US was "good", underpinning a third-quarter performance in line with its expectations.

The group said demand for its key luxury brands, particularly products on Registration of Interest lists, remains strong, outstripping supply in both the UK and US markets.

WOSG said it continues to be encouraged by the performance of its pre-owned businesses and the strong performance of the Roberto Coin brand in North America.

"Over the period, we have seen further stabilisation of the UK market in both luxury watches and jewellery, while the US market has seen continued momentum," it said. "In addition, our differentiated business model, alongside the continued investment in our showroom portfolio, has driven market share gains in both the UK and US."

It said the integration of the recent acquisitions of Hodinkee and Roberto Coin was progressing well and it is advancing a number of incremental growth plans with these businesses.

"Given our trading performance over the first nine months of the fiscal year, visibility of supply in both markets, certainty on the timing of key showroom openings, and expectations of new product launches, we remain confident in delivering our FY25 guidance," WOSG said.

Broker Shore Capital said: "Given the worsening views on the economic outlook of the UK, and a number of recent profit downgrades from retailers following a softer seasonal period, a report of good trading and maintained FY25F guidance should reassure."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.